Sat, Aug 2, 2014, 5:34 AM EDT - U.S. Markets closed


% | $
Click the to save as a favorite.

Questcor Pharmaceuticals, Inc. (QCOR) Message Board

  • lekinsh01 lekinsh01 Feb 17, 2013 10:06 PM Flag

    There is some reason for so many shorts in this company?

    Any one can explain me, why?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Herd mentality they're like wildebeasts running while gathering more,
      when they run off the cliff there won't be as many as there was before.

    • Okay seriously, The short thesis was that Insurance Providers were going to stop paying for the companies drug Acthar. This rumor was spread by manipulators who purchased Puts and sold calls right before releasing articles. There was a lot of misinformation provided to lead investors to believe the articles that were written. Since, many major Carriers have reaffirmed that they will be covering the drug, the short thesis is shot. Over the last month, shorts have lost the big money support. Large investors are going long. Company has a 7 million share buyback and instituted a dividend that pays about 2.8%. New VP has M&A experience. Technicals confirm a move up near future. Funny it coincides with earnings on the 26th. The company released its cash and cash equivalent position on Jan. 8th. Also announced record 4th qtr scripts shipped, just how big, we will see on the 26th. Some have been able to estimate it from the cash on hand announced with the acquistion of the supply line manufacturer BioVectra. Stock is not a short candidate at this time. Too much upside potential. Shorts will continue to cover their position this week as new investors pile in.

      Sentiment: Strong Buy

      • 2 Replies to itsawhiz
      • Itsawhiz--

        Well stated.
        Add in the company story: strong margins, robust top line growth, no near-term category competition, minor reimbursement issues typical of the biologics genre, and most of all...a therapy with demonstrated efficacy for a significant percentage of challenged patients, most of whom have already failed first line therapies.
        Not to go all humanist here, I'm as profit motivated as the next person...but periodically what makes my jaw drop a bit is the recklessness of analysts like MF or Leerink, or the disinformation specialists like Citron or Cramer. Ya know? If they want to attack Netflix or Green Mountain with half-witted premises, well ok, we're talking movies and coffee. But they ought to exercise a bit more caution with a company like QCOR, and they ought to responsibly mention, by the way, that the drug appears to offer a serious treatment option for compromised patient populations and the medical specialists who treat them...and maybe that's why revenue is growing.

        Sentiment: Strong Buy

      • itsawhiz - Well said!

        Sentiment: Strong Buy

    • Yep sure can........... There are alot of dumb people in this world.

      Sentiment: Strong Buy

89.99+0.02(+0.02%)Aug 1 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.